VENLO, Netherlands, January 31, 2018 /PRNewswire/ --
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2017, delivering on goals for adjusted net sales and adjusted earnings per share while driving the global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.
For the full press release click here
John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29 11711 and +1-240-686-2222 John.email@example.com
Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Sarah.firstname.lastname@example.org
Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 and +1-240-686-7425 Thomas.email@example.com
SOURCE Qiagen N.V.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All